Pacific Edge Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Pacific Edge prognostiziert ein Gewinnwachstum at 23.9% per annum. Der Gewinn pro Aktie wird voraussichtlich wachsen um 37.4% pro Jahr.

Wichtige Informationen

23.9%

Wachstumsrate der Gewinne

37.4%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	14.9%
Wachstumsrate der Einnahmen	n/a
Zukünftige Eigenkapitalrendite	-86.2%
Analystenabdeckung	Low
Zuletzt aktualisiert	27 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Pacific Edge Limited (NZSE:PEB) Annual Results: Here's What Analysts Are Forecasting For This Year

May 27

Recent updates

Investors Holding Back On Pacific Edge Limited (NZSE:PEB)

Apr 30

Here's Why We're Watching Pacific Edge's (NZSE:PEB) Cash Burn Situation

Feb 19

Lacklustre Performance Is Driving Pacific Edge Limited's (NZSE:PEB) 30% Price Drop

Dec 18

Fewer Investors Than Expected Jumping On Pacific Edge Limited (NZSE:PEB)

Jun 06

Pacific Edge Limited (NZSE:PEB) Annual Results: Here's What Analysts Are Forecasting For This Year

May 27

Don't Ignore The Fact That This Insider Just Sold Some Shares In Pacific Edge Limited (NZSE:PEB)

Mar 21

Did The Underlying Business Drive Pacific Edge's (NZSE:PEB) Lovely 750% Share Price Gain?

Mar 13

Have Insiders Been Selling Pacific Edge Limited (NZSE:PEB) Shares?

Feb 14

Pacific Edge Limited's (NZSE:PEB) Profit Outlook

Jan 18

How Much Of Pacific Edge Limited (NZSE:PEB) Do Insiders Own?

Dec 23

Did You Participate In Any Of Pacific Edge's (NZSE:PEB) Incredible 434% Return?

Nov 21

Gewinn- und Umsatzwachstumsprognosen

NZSE:PEB - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (NZD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
3/31/2024	25	-30	-27	-26	N/A
12/31/2023	25	-31	-28	-26	N/A
9/30/2023	26	-32	-29	-27	N/A
6/30/2023	23	-29	-29	-26	N/A
3/31/2023	21	-27	-28	-26	N/A
12/31/2022	19	-24	-27	-24	N/A
9/30/2022	16	-21	-25	-23	N/A
6/30/2022	15	-21	-22	-20	N/A
3/31/2022	13	-20	-19	-18	N/A
12/31/2021	12	-18	-17	-16	N/A
9/30/2021	12	-16	-15	-15	N/A
6/30/2021	10	-15	-15	-14	N/A
3/31/2021	9	-14	-14	-14	N/A
12/31/2020	7	-15	-15	-15	N/A
9/30/2020	6	-17	-16	-16	N/A
6/30/2020	5	-18	-16	-16	N/A
3/31/2020	5	-19	-16	-15	N/A
12/31/2019	5	-19	-16	-16	N/A
9/30/2019	5	-19	-16	-16	N/A
6/30/2019	5	-18	-17	-17	N/A
3/31/2019	5	-18	-18	-18	N/A
12/31/2018	5	-18	-17	-17	N/A
9/30/2018	5	-18	-17	-17	N/A
6/30/2018	5	-19	-18	-17	N/A
3/31/2018	5	-20	-18	-18	N/A
12/31/2017	4	-20	N/A	-19	N/A
9/30/2017	3	-21	N/A	-19	N/A
6/30/2017	4	-22	N/A	-18	N/A
3/31/2017	4	-23	N/A	-18	N/A
12/31/2016	6	-21	N/A	-18	N/A
9/30/2016	8	-20	N/A	-17	N/A
6/30/2016	7	-18	N/A	-17	N/A
3/31/2016	6	-16	N/A	-17	N/A
12/31/2015	5	-15	N/A	-16	N/A
9/30/2015	4	-15	N/A	-16	N/A
6/30/2015	4	-14	N/A	-14	N/A
3/31/2015	3	-12	N/A	-13	N/A
12/31/2014	3	-11	N/A	-12	N/A
9/30/2014	2	-10	N/A	-11	N/A
6/30/2014	1	-10	N/A	-10	N/A
3/31/2014	1	-10	N/A	-10	N/A
12/31/2013	0	-9	N/A	-9	N/A
9/30/2013	0	-9	N/A	-8	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: PEB wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: PEB wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: PEB wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von PEB schneller wachsen werden als der Markt von NZ.

Hohe Wachstumseinnahmen: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Einnahmen von PEB schneller wachsen werden als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: PEB wird voraussichtlich in 3 Jahren unrentabel sein.

Pacific Edge Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

No longer forecast to breakeven

Consensus EPS estimates upgraded to NZ$0.034 loss

Price target decreased by 7.8% to NZ$0.15

Price target decreased by 34% to NZ$0.38

Pacific Edge Limited (NZSE:PEB) Annual Results: Here's What Analysts Are Forecasting For This Year

Forecast to breakeven in 2026

Recent updates

Full year 2024 earnings released: NZ$0.036 loss per share (vs NZ$0.033 loss in FY 2023)

No longer forecast to breakeven

Pacific Edge Limited, Annual General Meeting, Sep 24, 2024

Pacific Edge Limited to Report Fiscal Year 2024 Results on May 21, 2024

Investors Holding Back On Pacific Edge Limited (NZSE:PEB)

Insufficient new directors

Pacific Edge Limited Announces Board Changes

Here's Why We're Watching Pacific Edge's (NZSE:PEB) Cash Burn Situation

Lacklustre Performance Is Driving Pacific Edge Limited's (NZSE:PEB) 30% Price Drop

Consensus EPS estimates upgraded to NZ$0.034 loss

First half 2024 earnings released: NZ$0.019 loss per share (vs NZ$0.013 loss in 1H 2023)

Pacific Edge Limited to Report First Half, 2024 Results on Nov 23, 2023

Price target decreased by 7.8% to NZ$0.15

Independent Non-Executive Director recently bought NZ$3.1m worth of stock

Key Executive recently bought NZ$54k worth of stock

Price target decreased by 34% to NZ$0.38

Pacific Edge Limited Announces Medicare Coverage of Cxbladder Tests in the US Market is Expected to Cease from 17 July 2023

Fewer Investors Than Expected Jumping On Pacific Edge Limited (NZSE:PEB)

Pacific Edge Limited (NZSE:PEB) Annual Results: Here's What Analysts Are Forecasting For This Year

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Forecast to breakeven in 2026

We're Hopeful That Pacific Edge (NZSE:PEB) Will Use Its Cash Wisely

Pacific Edge Announces the Acceptance for Publication of New Clinical Evidence That Shows Significant Improvements in the Performance of its Genomic Diagnostic Cxbladder Tests

Consensus forecasts updated

First half 2023 earnings released: NZ$0.013 loss per share (vs NZ$0.012 loss in 1H 2022)

Price target decreased to NZ$0.61

Companies Like Pacific Edge (NZSE:PEB) Are In A Position To Invest In Growth

Price target decreased to NZ$0.72

Pacific Edge Limited Appoints Darrell Morgan as Chief Operating Officer

Pacific Edge Limited to Report First Half, 2023 Results on Nov 26, 2022

Consensus revenue estimates fall by 27%

Pacific Edge (NZSE:PEB) Is In A Good Position To Deliver On Growth Plans

Now 26% undervalued after recent price drop

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to NZ$1.11

Pacific Edge Limited Announces It Is Advancing Its Clinical Evidence Generation Program with Lobster

Insufficient new directors

Consensus forecasts updated

Price target decreased to NZ$1.32

Pacific Edge (NZSE:PEB) Is In A Strong Position To Grow Its Business

Insufficient new directors

Consensus revenue estimates fall to NZ$12.9m

First half 2022 earnings: EPS and revenues exceed analyst expectations

No longer forecast to breakeven

CEO, MD & Executive Director exercised options to buy NZ$478k worth of stock.

Consensus EPS estimates fall to -NZ$0.014

We're Hopeful That Pacific Edge (NZSE:PEB) Will Use Its Cash Wisely

Full year 2021 earnings released: NZ$0.02 loss per share (vs NZ$0.032 loss in FY 2020)

Pacific Edge Limited (NZSE:PEB): Are Analysts Optimistic?

Insider recently sold NZ$130k worth of stock

Don't Ignore The Fact That This Insider Just Sold Some Shares In Pacific Edge Limited (NZSE:PEB)

Insider recently sold NZ$120k worth of stock

Did The Underlying Business Drive Pacific Edge's (NZSE:PEB) Lovely 750% Share Price Gain?

Have Insiders Been Selling Pacific Edge Limited (NZSE:PEB) Shares?

Analysts update estimates

Pacific Edge Limited's (NZSE:PEB) Profit Outlook

Pacific Edge Limited, Annual General Meeting, Jul 29, 2021

Pacific Edge Limited to Report First Half, 2022 Results on Nov 26, 2021

How Much Of Pacific Edge Limited (NZSE:PEB) Do Insiders Own?

New 90-day high: NZ$1.08

New 90-day high: NZ$0.78

First half 2021 earnings released: NZ$0.01 loss per share

Did You Participate In Any Of Pacific Edge's (NZSE:PEB) Incredible 434% Return?

Pacific Edge Limited Announces Management Changes

Pacific Edge Diagnostics Notifies the CMS LCD Coverage for Cxbladder

Pacific Edge Limited to Report Q2, 2021 Results on Nov 26, 2020

Insider recently sold NZ$258.2k worth of stock

Pacific Edge Limited announced that it expects to receive NZD 22 million in funding from ANZ New Zealand Investments Limited